Perth-listed biotech PharmAust has signed a deal with a leading Japanese chemical company that will give the ASX listed company rights to a library of 50 patents over promising anti-cancer agents. The new patents will complement the development of PharmAust’s main anti-cancer drug Monepantel, which has already shown positive results in fighting cancer.
Related Data & Insights
-
-
Rank Company Revenue 128th PharmAust $3.8m 129th ResApp Health $3.8m 130th Emyria $3.8m 132nd Botanix Pharmaceuticals $3.8m 133rd Volt Power Group $3.6m 200 listed industrial wa companies ranked by revenue.
Powered by Morningstar ®
Data & Insights
Mentioned Organisations
Mentioned People
Related Articles
05 Feb 2024
Board Moves February 5, 2024
28 Aug 2023
Board Moves August 28, 2023
30 Jun 2021
Perth funds progress projects world
Subscribe today for award-winning, unbiased and trusted journalism
Subscription OptionsX